source
- Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trialA Phase 3 study of a personalized mRNA vaccine for melanoma, developed by Merck and Moderna, showed a substantial improvement in patient outcomes. Patients receiving the vaccine together with Merc…
- Incyte reports strong early results for KRAS G12D inhibitor in pancreatic cancer, rivals RevMedIncyte presented phase 1 data at the European Society for Medical Oncology congress in Madrid, highlighting its KRAS G12D inhibitor INCB161734 combined with chemotherapy for pancreatic ductal adeno…